Provided by Tiger Trade Technology Pte. Ltd.

Aldeyra Therapeutics

1.77
-0.0700-3.80%
Post-market: 1.780.0100+0.56%19:13 EDT
Volume:2.61M
Turnover:4.66M
Market Cap:106.49M
PE:-3.14
High:1.84
Open:1.81
Low:1.76
Close:1.84
52wk High:6.73
52wk Low:1.07
Shares:60.16M
Float Shares:48.48M
Volume Ratio:0.40
T/O Rate:5.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5636
EPS(LYR):-0.5636
ROE:-58.73%
ROA:-24.95%
PB:2.41
PE(LYR):-3.14

Loading ...

Top Premarket Decliners

MT Newswires Live
·
Mar 17

Aldeyra options imply 10.9% move in share price post-earnings

TIPRANKS
·
Mar 06

Aldeyra FY 2025 R&D expense falls 46.8% to USD 25.7 million

Reuters
·
Feb 28

Aldeyra Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
Feb 25

Aldeyra Therapeutics CEO Todd Brady to Join Oppenheimer Healthcare Life Sciences Conference Fireside Chat

Reuters
·
Feb 18

Analysts Conflicted on These Healthcare Names: Arcturus Therapeutics (ARCT), Newron Pharmaceuticals SpA (OtherNWPHF) and Aldeyra Therapeutics (ALDX)

TIPRANKS
·
Jan 21

ATA Creativity Global Among 3 Promising Penny Stocks

Simply Wall St.
·
Jan 20

Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign

MT Newswires Live
·
Jan 02

Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer

Reuters
·
Jan 01

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

Dow Jones
·
Dec 16, 2025

Aldeyra Therapeutics Shares Drop 14.3% Premarket After Pdufa Extension of Its Drug Candidate for Dry Eye Disease Treatment

THOMSON REUTERS
·
Dec 16, 2025

BRIEF-Aldeyra Therapeutics Announces PDUFA Extension Of The New Drug Application Of Reproxalap For The Treatment Of Dry Eye Disease

Reuters
·
Dec 16, 2025

Aldeyra Therapeutics Announces Pdufa Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

THOMSON REUTERS
·
Dec 16, 2025

Aldeyra Therapeutics Inc - Extended Pdufa Target Action Date Is March 16, 2026

THOMSON REUTERS
·
Dec 16, 2025

Aldeyra Therapeutics Showcases Broad Immunology Pipeline Targeting Immune-Mediated Diseases in New R&D Presentation

Reuters
·
Nov 13, 2025

BRIEF-Aldeyra Therapeutics Announces Expansion of RASP Platform

Reuters
·
Nov 13, 2025

Aldeyra Therapeutics Reports Positive Preclinical Results for ADX-248 in Neurological Disease Models

Reuters
·
Nov 13, 2025

Aldeyra Therapeutics Announces Expansion of Rasp Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

THOMSON REUTERS
·
Nov 13, 2025

Aldeyra Therapeutics to Join Jefferies Global Healthcare Conference in London

Reuters
·
Nov 11, 2025

Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG

Dow Jones
·
Nov 10, 2025